Kimia Biosciences Limited has declared the voting results for its 33rd Annual General Meeting held on September 28, 2026. All ten resolutions proposed by the Board were passed with requisite majorities, confirming shareholder approval for expanded financial flexibility and governance changes.

The virtual meeting, conducted via Video Conferencing/Other Audio Visual Means, was chaired by Sameer Goel, Managing Director and CEO. The proceedings included the adoption of audited financial statements for FY26 and several appointments to the board. A shareholder speaker expressed satisfaction with the management's transparency and business continuity efforts.

Voting results overview

The scrutinizer's report, submitted by Maya Sharma & Associates, confirmed that no invalid votes were recorded across any resolution. The total number of shareholders on the record date was 12,751. While no shareholders attended in person or through proxy, 35 members participated via video conferencing (2 promoters and 33 public).

The following table summarizes the key voting outcomes for the special resolutions regarding financial mandates:

Key resolutions approved

The members passed both ordinary and special resolutions covering governance changes and financial authorizations. The special resolutions are particularly notable for granting the board broader powers regarding debt and asset encumbrance.

Governance and leadership updates

The meeting facilitated significant changes in the board composition. Sameer Goel was re-appointed in place of himself, retiring by rotation. New directors Amulya Kumar Nayak, Reema Goyal, and Avinash Prabhat were appointed, with Goyal and Prabhat joining as Independent Non-Executive Directors. This expansion of the independent director pool aims to strengthen oversight mechanisms.

Director profiles and terms

The company disclosed specific details regarding the newly appointed directors, including their expertise and tenure:

• Sameer Goel: Managing Director/Director, re-appointed on September 28, 2026. He holds a 74.94% shareholding in the company. His background includes extensive experience in the Indian pharmaceutical/API sector, business development, and strategic marketing.
• Amulya Kumar Nayak: Appointed as Director liable to retire by rotation on September 28, 2026. He is a finance and accounts professional with over 32 years of experience in taxation, audit, MIS, and corporate finance, having worked with firms like Punj Lloyd Ltd. and GTL Ltd.
• Reema Goyal: Appointed as Independent & Non-Executive Woman Director. Her term runs for five consecutive years from April 4, 2026, to April 3, 2031. She is a Company Secretary in Practice with over five years of experience in corporate law and SEBI regulations.
• Avinash Prabhat: Appointed as Independent & Non-Executive Director. His term also runs for five consecutive years from April 4, 2026, to April 3, 2031. He is a Company Secretary with over five years of experience in governance and statutory compliance.

None of the appointed directors hold shareholding in the company except for Sameer Goel, and none are debarred by SEBI or other authorities.

Strategic implications of financial mandates

The approval of special resolutions to increase borrowing limits and create charges on assets indicates a preparatory step for potential capital expenditure or operational funding needs. By securing these authorizations in advance, the board retains the flexibility to leverage its balance sheet without requiring immediate shareholder intervention for specific debt instruments. The simultaneous approval of limits under Sections 185 and 186 further suggests a structured approach to inter-corporate transactions and investments.

Voting results and the scrutinizer's report have been submitted to BSE Limited and hosted on the company website within the prescribed timeline under SEBI regulations.

Kimia Biosciences Limited has announced the closure of its trading window effective October 1, 2026. The restriction will remain in place until 48 hours after the declaration of the unaudited financial results for the quarter and half-year ended September 30, 2026.

Regulatory compliance and scope

The decision is taken pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended. It aligns with the company's internal Code of Conduct for regulating, monitoring, and reporting of trading by designated persons. The closure applies to all promoters, members of the promoter group, directors, designated persons, their immediate relatives, and other individuals covered under the code.

Board meeting schedule

The specific date for the board meeting to consider and approve the financial results has not been finalized. Kimia Biosciences stated that this date will be intimated separately in due course, in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key details of the trading window closure